People channel feed

Daniel O’Day snatch­es an­oth­er I/O com­pa­ny, buy­ing half of a pi­o­neer­ing can­cer drug dis­cov­er­er's biotech

5 years ago
Deals

Promi­nent Har­vard pro­fes­sor in the hunt for $100M to back his an­ti-ag­ing play

5 years ago
Financing

UP­DAT­ED Dew­point nabs ex-Sanofi CEO Brandi­court and Bay­er VC chief Eck­hardt for board

5 years ago

A pi­o­neer­ing im­muno-on­col­o­gy re­searcher heads back to Dana-Far­ber as Eli Lil­ly’s can­cer R&D group un­der­goes a wrench­ing change­up

5 years ago
R&D

Har­vard's Charles Lieber in­dict­ed for ly­ing to the feds, bring­ing US re­searcher­s' Chi­na ties back to the spot­light

5 years ago
China

Lean­ing on BD to re­vive weak pipeline, Lund­beck plans to cut up to 160 jobs in R&D re­struc­tur­ing

5 years ago
R&D

Mod­er­na’s new CFO took a cut in salary to jump to the mR­NA rev­o­lu­tion­ary. But then there’s the rest of the com­pen­sa­tion pack­age

5 years ago

Drug man­u­fac­tur­ing gi­ant Lon­za taps Roche/phar­ma ‘rein­ven­tion’ vet as its new CEO

5 years ago
Outsourcing

Am­gen vet David Meline finds a new CFO roost at Mod­er­na, tak­ing a ride on the Covid-19 tiger as de­part­ing ex­ec cash­es out with $12M

5 years ago

Cameron Dur­rant hus­tled his way from the OTC side­lines right in­to the Covid-19 drug race. Death or glo­ry lies straight ahead

5 years ago
Bioregnum
Coronavirus

Why Mer­ck wait­ed, and what they now bring to the Covid-19 fight

5 years ago
R&D
In Focus

Gilead woos fil­go­tinib clin­i­cal in­ves­ti­ga­tor from Stan­ford to lead the charge on NASH, in­flam­ma­to­ry dis­eases

5 years ago

Once a high fly­er, a stag­ger­ing Aduro is auc­tion­ing off most of the pipeline as CEO Stephen Isaacs hands off the shell to new own­ers

5 years ago
Deals

Sanofi brings in 4 new ex­ec­u­tives in con­tin­ued shake-up, as vac­cines and con­sumer health chief head out the door

5 years ago
Peer Review

Look­ing to move past an R&D fi­as­co, Ipsen poach­es their new CEO from Sanofi

5 years ago
Peer Review

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

5 years ago
Pharma

Drug de­vel­op­er, Big Phar­ma com­mer­cial ex­ec, now an up­start biotech chief — Fab­rice Chouraqui is ready to try some­thing new as a ‘CEO-part­ner’ at Flag­ship

5 years ago
R&D

Stymied by the pan­dem­ic, Im­munomedic­s' new CEO bows out, tak­ing a mil­lion bucks plus perks as he heads out the vir­tu­al ex­it

5 years ago

Ex-biotech chief pleads guilty in col­lege ad­mis­sions scan­dal, faces a 10-month prison stretch in plea deal

5 years ago

An­dreessen Horowitz backs a new mol­e­cule builder from UCLA equipped with the lat­est in con­ver­gence tech. And he’s aim­ing big

5 years ago
Financing

No­var­tis taps Iya Khalil, physi­cist co-founder of GNS Health­care, to lead AI In­no­va­tion Cen­ter

5 years ago
AI

Mon­cef Slaoui piv­ots from Mod­er­na's board to the helm of Project Warp Speed. His task: Overnight suc­cess

5 years ago
Bioregnum
R&D

Rick Bright de­tails mis­man­aged pan­dem­ic re­sponse, warns of drugs, vac­cine sup­ply prob­lems down the road; HHS push­es back

5 years ago
Coronavirus

BIO gets a new chief lob­by­ist to face off against the grow­ing ranks of crit­ics in Con­gress

5 years ago
Bioregnum
Opinion
First page Previous page 67686970717273 Next page Last page
A service from the Financial Times